U.S. Markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.91+0.39 (+2.51%)
At close: 4:00PM EDT
14.95 -0.95 (-6.00%)
After hours: 05:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.52
Open16.10
Bid14.01 x 1000
Ask17.50 x 1000
Day's Range15.41 - 16.10
52 Week Range12.25 - 17.99
Volume12,664
Avg. Volume21,187
Market Cap546.162M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
  • The Telegraph

    Taxpayer takes stake in Oxford vaccine co-creator

    The British taxpayer has become a shareholder in an online store for knitting, an at-home beautician service and the Secret Cinema following an effort to rescue startups struggling to survive the pandemic.

  • GlobeNewswire

    Vaccitech to Present at Upcoming September Investor conferences

    OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September. Event:Morgan Stanley Healthcare Conference 2021Date:Thursday, September 9Presentation

  • GlobeNewswire

    Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. “The second quarter of 2021 was our first as a publ